Nomenclature	5‐HT 2A receptor	5‐HT 2B receptor
HGNC, UniProt	HTR2A, P28223	HTR2B, P41595
Agonists	DOI [210, 1438, 1825]	methysergide (Partial agonist) [1018, 1679, 2053], DOI [1077, 1438, 1730]
Selective agonists	–	BW723C86 [115, 1018, 1730], Ro 60‐0175 [1018]
Antagonists	risperidone (Inverse agonist) (pK i 9.3–10) [1032, 1055, 1746], mianserin (pK i 7.7–9.6) [1018, 1045, 1338], ziprasidone (pK i 8.8–9.5) [1032, 1055, 1746, 1782], volinanserin (pIC50 6.5–9.3) [1018, 1208, 1640], blonanserin (pK i 9.1) [1487], clozapine (Inverse agonist) (pK i 7.6–9) [1018, 1055, 1335, 1746, 2022]	mianserin (pK i 7.9–8.8) [184, 1018, 2053]
Selective antagonists	ketanserin (pK i 8.1–9.7) [241, 1018, 1630], pimavanserin (Inverse agonist) (pK i 9.3) [603, 2022]	BF‐1 (pK i 10.1) [1742], RS‐127445 (pK i 9–9.5) [184, 1018], EGIS‐7625 (pK i 9) [1045]
Labelled ligands	[3 H]fananserin (Antagonist) (pK d 9.9) [1251] – Rat, [3 H]ketanserin (Antagonist) (pK d 8.6–9.7) [1018, 1630], [11 C]volinanserin (Antagonist) [712], [18 F]altanserin (Antagonist) [1675]	[3 H]LSD (Agonist) [1630], [3 H]5‐HT (Agonist) [2051] – Rat, [3 H]mesulergine (Antagonist, Inverse agonist) (pK d 7.9) [1018], [125 I]DOI (Agonist)